Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer

Breast Cancer Research and Treatment

Volumn 65, Issue 2, 2001, Pages 135-144

  Kenny, F S ^a   Willsher, P C ^a   Gee, J M W ^a   Nicholson, R I ^a   Pinder, S E ^b   Ellis, I O ^b   Robertson, J F R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Endocrine response; ER; MIB1; Primary tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035127192     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006469627067     Document Type: Article

References (50)

1. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer
2. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
3. Assessment of response to treatment in advanced breast cancer
4. Assessment of response to treatment in advanced breast cancer
5. Cellular effects of primary tamoxifen in breast cancer
6. Oestrogen receptor: A stable phenotype in breast cancer
7. Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirate
8. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
9. Investigation of a new pure anti-oestrogen (ICI 182,780) in women with primary breast cancer
10. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor and transforming growth factor-alpha protein expression in human breast cancer
11. The anti-tumor effects of single dose, long acting Faslodex (ICI 182,780) compared with Tamoxifen in post-menopausal primary breast surgery patients treated before surgery
12. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer
13. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer
14. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
15. pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients
16. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer
17. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples
18. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods
19. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: A comparison with frozen section methodology
20. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating in micro-wave processed formalin-fixed paraffin sections
21. Use of tamoxifen for breast cancer: Twenty-eight years later
22. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
23. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
24. Modulation of bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen
25. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells
26. Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation
27. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
28. The expression of Ki-S1 and bcl-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
29. Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
30. Bcl-2 and the regulation of programmed cell death
31. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
32. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity
33. Prognostic value of bcl-2 expression in invasive breast cancer
34. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis
35. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables
36. Clinical significance of bcl-2 gene expression in human breast cancer tissues
37. Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and n-myc amplification
38. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
39. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model
40. Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent human breast cancer cells
41. Mechanisms of hormone response: A role for apoptosis
42. Cytological evaluation of biological variables in breast cancer patients undergoing primary medical treatment
43. Increase of progesterone receptor by tamoxifen as a hormonal challenge in breast cancer
44. Endocrine therapy for advanced carcinoma of the breast: Relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment
45. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behaviour over time
46. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer
47. Pure anti-estrogens in breast cancer: Experimental and clinical observations
48. Effects of short-term anti-estrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes
49. A potent specific pure antiestrogen with clinical potential